We studied the influence of the aromatic sidewalls on the ability of acyclic CB[n]-type molecular containers (1a−1e) to act as solubilizing agents for 19 insoluble drugs including the developmental anticancer agent PBS-1086. All five containers exhibit good water solubility and weak self-association (K s ≤ 624 M −1 ). We constructed phase solubility diagrams to extract K rel and K a values for the container· drug complexes. The acyclic CB[n]-type containers generally display significantly higher K a values than HP-β-CD toward drugs. Containers 1a−1e bind the steroidal ring system and aromatic moieties of insoluble drugs. Compound 1b displays highest affinity toward most of the drugs studied. Containers 1a and 1b are broadly applicable and can be used to formulate a wider variety of insoluble drugs than was previously possible with cyclodextrin technology. For drugs that are solubilized by both HP-β-CD and 1a−1e, lower concentrations of 1a−1e are required to achieve identical [drug].
■ INTRODUCTION
Molecular container compounds have been extensively studied over the years by synthetic, supramolecular, materials, and medicinal chemists by virtue of their ability to alter the properties of compounds bound within their interior. Some of the best-investigated classes of molecular container compounds include crown ethers, cryptands, carcerands, calixarenes, cyclophanes, cyclodextrins, and complexes self-assembled by metal·ligand and H-bonding interactions as well as reversible covalent bonds.
1 For example, encapsulation inside molecular containers can reduce the reactivity of highly reactive species like P 4 , reduce the odor of malodorous compounds, promote the reactions of included substrates, provide the basis of stimuli responsive molecular machines, enhance the photophysical properties of encapsulated dyes, and even reverse the toxic effects of certain compounds.
1f,2 We, and others, have been studying an alternative class of molecular containers known as cucurbit [n] urils (CB[n] , n = 5, 6, 7, 8, 10, Figure 1 ).
3 CB[n] compounds are particularly attractive because of the remarkably high affinity, selectivity, and stimuli responsiveness that they display toward their guests in aqueous solution. 4 For these reasons, CB[n] compounds have been used as key components in the construction of functional supramolecular systems including affinity separation phases, supramolecular velcro, surface enhanced Raman scattering sensing, and for biomembrane assays. 5 An urgent problem facing the pharmaceutical industry is that a high percentage of new chemical entities with documented target affinity are so poorly soluble that formulation is challenging. 6 A number of techniques and tools have been developed to address the drug solubility issue including the generation of nanocrystalline solid forms of the drug, salt formation, solid dispersions, and higher solubility prodrugs. 7 Of highest relevance to supramolecular chemists, however, is the use of the cyclodextrin derivatives hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutyl ether-β-cyclodextrin (SBE-β-CD, Figure 1 ) to improve the solubility of insoluble drugs by encapsulation inside the molecular containers. 8 A number of drugs are formulated for administration to humans by encapsulation inside HP-β-CD and SBE-β-CD. Accordingly, researchers in the CB [n] area are exploring their use in this class of applications. For example, CB [n] have been used to increase the solubility of a number of insoluble drugs (e.g., albendazole, chlorambucil, camptothecin) , to retard degradation reactions, and for targeted drug delivery. 9 The Isaacs group has been interested in understanding the mechanism of CB[n] formation and using that information to prepare CB[n]-type receptors with new structural features and recognition properties. 10 In 2012, we reported the synthesis of acyclic CB[n]-type receptor 1a and its use as a solubilizing excipient for insoluble drugs. Compound 1a and relatives have three main structural features: (1) a central glycoluril oligomer to impart curvature and the ability to bind to hydrophobic and cationic species, (2) terminal aromatic walls to promote π−π interactions between container and insoluble drug, and (3) solubilizing sulfonate arms that result in high solubility.
11
Compound 1a is not toxic in in vitro and in vivo assays, and paclitaxel (8) formulated as 1a·paclitaxel maintains its ability to efficiently kill HeLa cells. 11c We also showed that acyclic CB[n]-type container 1b and relatives are capable of in vivo reversal (in rats) of the biological effects of rocuronium which is a neuromuscular blocking agent commonly used by anesthesiologists during surgery.
11d Previously, we studied the influence of the nature of the solubilizing groups (e.g., SO 3 − vs OH vs NH 3 + ) on the ability of acyclic CB[n] type containers to act as solubilizing agents for insoluble drugs and found that sulfonate groups are particularly well-suited for this application because they impart high solubility in water and do not promote self-folding and complexation (e.g., as NH 3 + does).
12
In this Article we explore the influence of the nature of the aromatic sidewalls on the ability of the acyclic CB[n]-type 11c,e,12 Compounds 1a−1e differ in the nature of their aromatic sidewalls (e.g., benzene, naphthalene, tetrahydronaphthalene). These structural differences impact the conformation of the uncomplexed container (e.g., smaller, larger, taller cavity) and the type and balance of noncovalent interactions (e.g., π−π versus dispersion interactions) that form in the container·drug complexes. For example, the X-ray crystal structures of 1a show that the tips of the substituted benzene sidewalls are in close contact with one another.
11c Therefore, to accommodate the longer naphthalene sidewalls of 1b, the glycoluril tetramer backbone of 1b flexes which results in a larger cavity that is defined in larger part by the aromatic naphthalene sidewalls.
11c Compound 1c is an isomer of 1b; in this case the sidewalls are shorter and deeper by virtue of the attachment at the naphthalene 1,8 positions.
11e To prepare new acyclic CB[n] type receptors 1d and 1e which possess alkyl substituted sidewalls we needed to prepare compounds 3d and 3e. Accordingly, we reacted 2,3-dimethylhydroquinone with 1,3-propane sultone (4) under basic conditions (NaOH) in dioxane at room temperature to give 3d in 73% yield (Scheme 1a). Sidewall 3e was prepared by a multistep procedure (Scheme 1b). First, we performed the Diels−Alder reaction between benzoquinone and 1,3-butadiene in toluene to give 5 in 92% yield. 13 Next, we aromatized 5 by treatment with HBr to give 6 in 82% yield. 13 Subsequently, we reduced the double bond of 6 under standard conditions to give 7 in 85% yield. 14 Finally, 7 was reacted with 4 under basic conditions to give the required aromatic wall 3e in 60% yield. The reaction of glycoluril tetramer 2 with sidewall 3d (4 equiv) in a 1:1 (v:v) mixture of TFA:Ac 2 O at 70°C gave acyclic CB[n] type container 1d in 43% yield. Similarly, the reaction of 2 with 3e (4 equiv) gave container 1e in 30% yield.
Solubility Properties of the Acyclic CB[n]-type Containers 1a−1e. An important property of a container that is to be used as a solubilizing excipient for insoluble drugs is the inherent solubility of the container alone. Previously, we have reported the solubility of 1a and 1b in 20 mM sodium phosphate buffered D 2 O at pD 7.4 as 105 and 14 mM, respectively. We used the methodology reported previously, 11c,12 1 H NMR assay in the presence of 1,3,5-benzene tricarboxylic acid as internal standard of known concentration, to determine the inherent solubilities of 1c (115 mM), 1d (353 mM), and 1e (145 mM). The high solubilities of 1a, 1c, 1d, and 1e make them particularly attractive as solubilizing excipients for insoluble drugs. 16 Finally, we performed a dilution experiment for 1e (35−0.2 mM) and observed both broadening and changes in 1 H NMR chemical shifts. Unfortunately, the changes in chemical shift could not be fitted to the standard 2-fold self-association model, and we believe that 1e undergoes more complex higher order aggregation. The generally weak self-association observed for 1a−1e is advantageous toward their use as solubilizing excipients for insoluble drugs because the container is free to associate with drug without having to overcome strong selfassocation.
Theoretical Treatment of Phase Solubility Diagrams. PSDs are plots of [Drug] as a function of [Container] that are commonly used to study the ability of molecular containers to increase the solubility of insoluble drugs. 15, 17 These PSDs can assume a variety of shapes, but linear PSDs (A L -type) are most common and occur when container and guest form soluble well-defined 1:1 container·guest complexes. Such PSDs behave according to eq 1 where S 0 is the solubility of drug alone and K a is the binding constant for the container·drug complex. The slope of an A L -type PSD simply reflects the ratio of the increase in concentration of drug obtained relative to the concentration of container used. Container·drug systems that display larger PSD slopes (e.g., slope ≥0.5) are advantageous because larger concentrations of drug can be obtained with smaller concentrations of container. Figure 3 shows the results of two simulations that were performed on a hypothetical container·drug system that obeys eq 1 to stimulate the discussion and analysis of the experimental PSDs created for containers 1a−1e and HP-β-CD with drugs 8−26 shown in Figure 2 . Figure 3a shows the calculated PSDs for five different containers and a single drug with S 0 = 1 × 10 −6 M which form well-defined 1:1 container·drug complexes of high solubility. The different K a values for the different container·drug complexes translate into PSDs with different slopes. For example, a change in slope from 0.1 to 0.5 and from 0.5 to 0.9 each corresponds to a 9-fold increase of K a . Importantly, a precise knowledge of S 0 is not necessary in order to calculate relative K a values (K rel = K a,C1·D1 /K a,C2·D1 ) from the PSDs obtained with two different containers (e.g., C1 and C2) toward a common drug (e.g., D1) because the S 0 values cancel as shown in eq 2. If S 0 is known precisely, then absolute K a values can be calculated using eq 1. Figure 3b shows a plot of the slope of the PSD as a function of the K a for the container· drug complex for five different values of S 0 (1 mM, 100 μM, 10 μM, 1 μM, 0.1 μM). Clearly, the lower the inherent solubility of the drug (S 0 ), the higher the value of K a needed to result in a PSD of comparable slope. As a special case of eq 1, consider the situation when (K a )(S 0 ) = 1; under this constraint, then slope = 0.5 ( Figure 3b ). From a practical point of view this means that to efficiently solubilize an insoluble drug (e.g., slope of PSD = 0.5) with an inherent solubility of 10 μM (100 nM) requires a K a value of 10 5 M −1 (10 7 M
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). In theory, the high values of K a that are typically observed for CB[n]-type receptors promise to enable the solubilization of drugs whose solubilities are too low to be solubilized by lower affinity hosts (e.g., cyclodextrins).
(1)
(2)
Use of 1a−1e as Solubilizing Agents for Insoluble Drugs. In order to more fully understand the correlation between container structure (e.g., 1a−1e), drug structure and properties, and the ability of the containers to solubilize insoluble drugs, we created PSDs for containers 1a−1e and HP-β-CD with the 19 insoluble drugs (8−26) shown in Figure  2 . Of these, 18 are drugs currently used in practice along with PBS-1086 (17) which is a developmental compound with documented anticancer activity. 18 To create these PSDs we stir an excess of insoluble drug with a known concentration of container until equilibrium is achieved, then remove remaining insoluble drug by filtration or centrifugation, and measure the concentration of drug in the supernatant by 1 H NMR spectroscopy. Our 1 H NMR assay relies on the addition of a known concentration of 1,3,5-benzene tricarboxylic acid as a nonbinding internal standard of known concentration which allows us to use the ratio of the integrals for drug versus internal standard to measure drug concentration. We have measured full PSDs for all 19 drugs with the six containers (Supporting Information). In nearly all cases, linear PSDs were observed at low [container] indicative of well-defined 1:1 complex formation, although some of the PSDs display plateau regions at higher [container] which indicates that the solubility of the container·drug complex is lower than that of the uncomplexed container. Table 1 gives the initial slopes of the PSDs determined by linear regression for all container−drug combinations. Table 1 also presents the K rel values calculated using eq 2 referenced to the weakest binding host (usually HP-β-CD with K rel = 1). The uncertainties in K rel are generally ≈10−20%, although larger uncertainties are noted for PSDs with slope greater than 0.8. Figure 4 presents (24)], 1b forms such tight complexes (slope ≈1) that it is not possible to calculate a K rel value using eq 1. Acyclic CB[n]-type containers including 1a and 1b are known to be relatively flexible 11f,19 and often exhibit an out-ofplane distortion (e.g., helical twist) as they wrap around their guests. Accordingly, each container·drug complex will exhibit a different geometry based on the size, shape, and functionality of the drug. However, we offer some rationale for the observed superior performance of 1b. Figure 5 shows the previously reported X-ray structures of 1a and 1b as their CF 3 CO 2 H solvates.
11c First, the size of the cavity of 1b is larger than that of 1a as measured by the distance between the opposing quaternary C atoms (1a, 10.93 and 11.44 Å; 1b, 11.99 and 12. 90 Å) of the dimethylglycoluril units. The increased size of 1b is caused by its longer naphthalene sidewalls (relative to 1a) which would clash sterically in a more compact geometry. Second, the naphthalene walls of 1b engage in edge-to-face π−π interactions with one another that creates a large hydrophobic π-surface that should allow it to simultaneously engage in edge-to-face and offset face-to-face π−π interactions with insoluble aromatic drugs. Containers 1d and 1e which feature Me and cyclohexyl substituted o-xylylene sidewalls should possess larger cavities than 1a; however, the alkyl substitution reduces the available π-surface area which should decrease their affinity toward insoluble aromatic compounds. For container 1c, the isomeric naphthalene sidewalls are of comparable length to 1a and result in a narrow and deep cavity. Accordingly, we surmise that the length of the naphthalene walls of 1b and their ability to define a hydrophobic box of large π-surface area makes 1b a superior solubilizing agent relative to containers 1a and 1c−1e.
Solubilization of Steroids. The test panel of insoluble drugs contained three steroids [estradiol (18), 17-α-ethynylestradiol (19) , and fulvestrant (25)]. Steroids can often be solubilized with HP-β-CD, which allows a head-to-head comparison with 
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2.7 ± 0.34 0.12 ± 0.0041 9.4 ± 0.45 0.48 ± 0.076 62 ± 13 0.026 ± 0.0032 1.8 ± 0.23 5.1(±0.67) × 10 1e Figure 4a shows the PSDs measured for all six containers toward estradiol (18) which is illustrative. All five acyclic CB[n]-type containers 1a−1e solubilize estradiol more efficiently (slope = 0.35 to 0.92; K rel from 2.4 to 51) than HP-β-CD (slope =0.18; K rel = 1.0). Figure 6a−c shows the 1 H NMR spectra recorded for estradiol alone in and in the presence of 1a and 1b in buffered D 2 O. The large upfield shifts observed for the axial Me-group (H k ) and the protons on the sp 3 -hydridized C atoms of the steroidal skeleton indicate that the containers bind preferentially to this region of the steroids. Container 1b solubilizes 17-α-ethynylestradiol (19) with 1:1 stoichiometry which is indicative of a very large association constant K a for this complex. Only container 1b was capable of solubilizing fulvestrant (25) which is both highly hydrophobic and fluorinated. Previously, we have established that 1b binds to the neuromuscular blocking agents rocuronium and vecuronium which are steroidal diammoniums with K a > 10 9 M −1 . 11d In combination, these results allow us to conclude that acyclic CB[n]-type containers (but especially 1b) are better receptors for steroids than HP-β-CD.
Developmental Anticancer Agent 17. Compound 17 is a developmental drug with documented in vivo anticancer activity using a DMSO formulation, but which could not be formulated in water using the standard techniques including cyclodextrins.
18a Accordingly, we decided to investigate the formulation of 17 using containers 1a−1e (Table 1 and Figure  4b ). All five acyclic CB[n]-type containers solubilize 17 (slope = 0.14−0.89) whereas HP-β-CD is incapable of solubilizing this drug. Interestingly, although 17 is most efficiently solubilized by 1b (slope = 0.89), container 1a (slope = 0.71) generates a solution with the highest concentration of 17 because of the higher inherent solubility of 1a. Compound 17 is also nicely solubilized by 1d which is perhaps unsurprising given that the Table 1. continued   1d 1e
38 ± 1.6 0.83 ± 0.063 17 ± 6.7 0.87 ± 0.054 22 ± 9.3 0.22 ± 0.018 1.0 1.3(±0.51) × 10 Acyclic CB[n]-type Containers Are Good Solubilizing Agents for Insoluble Drugs Containing Aromatic Rings. The X-ray crystal structures of 1a and 1b ( Figure 5) show that the aromatic sidewalls are oriented roughly perpendicular to one another and define a hydrophobic box. Accordingly, it would be expected that insoluble drugs that contain aromatic rings would be good guests for acyclic CB[n]-type containers. The majority of drugs studied in this paper contain aromatic rings within their structure, and we generally observed upfield shifting of the 1 H NMR resonances of these aromatic rings upon complexation with 1a−1e. Those aromatic rings with attached ammonium functional groups (e.g., anilines, benzimidazoles, N-arylpiperazines) constitute preferred binding sites. In only one case (amiodarone, 13) was complexation at an aliphatic ammonium (Pr 2 NHR + ) moiety predominant. The observed upfield shifting of the aromatic protons confirms that the aromatic residues of the drugs are encapsulated within the hydrophobic box that is defined by the two aromatic walls and the methylene bridged glycoluril tetramer backbone. For example, Figure 6d−f shows the 1 H NMR spectra recorded for camptothecin (14) alone in and in water in the presence of containers 1d and 1b. Obviously, the protons on the aromatic rings of camptothecin (H a −H f ) undergo substantial upfield shifts upon complexation. Larger upfield shifts are observed upon complexation with 1b probably because of the larger anisotropic shielding effect of the naphthalene walls of 1b relative to the o-xylylene walls of 1d. Figure 4c shows the PSDs created for mixtures of camptothecin (14) with containers 1a−1e and HP-β-CD which display A Ltype PSDs indicative of 1:1 complexation. All five acyclic CB[n]-type containers (1a−1e) solubilize camptothecin (14) nicely, with 1b doing so in equimolar amounts whereas HP-β-CD is unable to solubilize camptothecin under these conditions. Among containers 1a−1e, container 1e displays the narrowest scope of solubilizing abilities with 9 out of 19 drugs displaying no solubilization. We attribute the poor solubilization abilities of 1e to the half-chair conformation of its tetrahydronaphthalene walls which sterically impede π−π interactions. We believe that the strategic merging of the structural features of CB[n] receptors (to deliver strong hydrophobic binding and ammonium binding) with the aromatic walls of cyclophanes to impart affinity toward the wide variety of insoluble aromatic drugs positions acyclic CB[n]-type receptors as a powerful alternative to cyclodextrins that expands the scope of insoluble drugs that can be formulated with molecular container technology.
Some Drugs Are Solubilized by a Narrow Set of Containers. Four drugs are solubilized by only one acyclic CB[n]-type container: paclitaxel (8) and docetaxel (23) by 1a, fenofibrate (22) and fulvestrant (25) by 1b. Cinnarizine (12) is only solubilized by two containers; it is best solubilized by 1a and less well by 1e. On the basis of this data we believe that containers 1a and 1b are the most versatile and general purpose solubilizing agents and that these containers are best positioned for further development as novel solubilizing excipients for practical applications.
Container 1d Is Structurally and Functionally Intermediate between 1a and 1b. The dimethyl substituted o-xylylene walls of container 1d are intermediate in length between 1a and 1b which feature benzene and napthalene derived sidewalls. Compound 1d is also intermediate between 1a and 1b in terms of its self-association properties but possesses superior solubility characteristics (353 mM) in buffered water. Accordingly, and perhaps unsurprisingly, we find that 1d exhibits solubilization abilities that are similar to those of 1a and 1b. For example, for albendazole (9), melphalan (10), amiodarone (13) , indomethacin (15) , and tolfenamic acid (16), the slopes and K rel values for 1d are comparable to those of 1a but significantly smaller than the corresponding values measured for 1b. For other drugs, namely voriconazole (24) and ziprasidone (26), the slope and K rel values measured for 1d are more comparable to those of 1b than 1a.
Comparison of the Binding Affinity of 1a−1e with HP-β-CD toward Insoluble Drugs. It is also possible to determine the absolute K a value for container·drug complexes from the PSDs if the solubility of the uncomplexed drug (S 0 ) is known. Accordingly, we measured the inherent solubility for 13 of the 19 drugs studied and used these S 0 values to determine the absolute K a values for this selection of drugs as given in Table 1 . The binding constants for these 13 drugs toward HP-β-CD span the range 160−36 000 M −1 which is in line with the well-known low affinity (log K a = 2.5 ± 1.1 M −1 ) and low selectivity of cyclodextrins toward their guests. 20 In contrast, the K a values measured for these 13 drugs toward 1a−1e fall in the range 1300 to 1.9 × 10 6 M −1 with three additional complexes too tight to measure using the PSD. For drugs that are solubilized by HP-β-CD, the best acyclic container (e.g., 1a−1e) always forms significantly stronger container·drug complexes (29-to 630-fold stronger) than HP-β-CD. In many cases the acyclic containers bind to and solubilize drugs [e.g., camptothecin (14) and aripiprazole (21)] that cannot be solubilized at all with HP-β-CD under these conditions. The ability of 1a−1e to solubilize drugs that cannot be solubilized with HP-β-CD and to do so more efficiently (larger slope and K a ) suggests that acyclic CB[n]-type containers will become an important tool to formulate insoluble pharmaceutical agents.
■ CONCLUSIONS
In summary, we have compared the ability of 1a−1e to solubilize insoluble drugs relative to HP-β-CD. Compounds 1a−1e do not undergo strong self-association (K s ≤ 624 M −1 ) in buffered water and possess good solubility characteristics. We created PSDs for mixtures of containers 1a−1e and HP-β-CD with 19 drugs. We find that the solubilizing ability of the best container (1a−1e) is superior to HP-β-CD in all cases; 1a−1e even solubilize 8 drugs that are completely insoluble with HP-β-CD. The superior solubilizing ability can be traced to the 29-to 630-fold higher binding affinity of the best acyclic CB[n]-type container toward the drugs compared to HP-β-CD. Less container is needed, therefore, to achieve a given [drug] . A notable achievement was the solubilization of the developmental anticancer agent 17. The acyclic CB[n]-type containers display an affinity for the steroid ring system, aromatic moieties of insoluble drugs, and cationic ammonium groups. Compound 1b is generally the most potent (K a up to and exceeding 10 6 M −1 ) container whereas both 1a and 1b display excellent solubility enhancement toward a broad range of insoluble drugs. The broad scope of insoluble drugs that can be formulated with 1a and 1b, in many cases where HP-β-CD fails completely, makes acyclic CB[n]-type containers particularly attractive alternatives to cyclodextrins as solubilizing excipients for practical applications.
■ EXPERIMENTAL SECTION
General Experimental. Starting materials were purchased from commercial suppliers and were used without further purification. Compounds 1a−1c, 2, 5, and 6 were prepared according to literature procedures. 11b,c,e,13 Melting points were measured on a Meltemp apparatus in open capillary tubes and are uncorrected. IR spectra were measured on a JASCO FT/IR 4100 spectrometer by attenuated total reflectance (ATR) and are reported in cm −1 . NMR spectra were measured at 400 or 600 MHz for 1 H and 125 MHz for 13 C. Integration of the 1 H NMR spectra indicates that the new compounds have a level of purity ≥95%. Mass spectrometry was performed using a JEOL AccuTOF electrospray instrument using the electrospray ionization technique.
1 -P r o p a n e s u l f o n i c A c i d , 2 , 3 , 1 5 , 1 6 -T e t r a m e t h y l -3, 3′,3″,3‴-[[(19bα,19cα,21bα,21cα,23bα,23cα,25bα,25cα)-5,13,18, 19b,19c,21b,21c,23b,23c,25b,25c,26-dodecahydro-19b,19c,25b, 25c-tetramethyl-6,8,10,12,19,21,23,25-octaoxo-6H,7H,8H,9H,10H, 11H,12H,19H,20H,21H,22H,23H,24H,25H-5a,6a,7a,8a,9a,10a,11a, 12a,18a,19a,20a,21a,22a,23a,24a,25a-hexadecaazabisbenzo-[5″,6″] 2952w, 2875w, 1733s, 1652s, 1474s, 1368m, 1321m, 1233s, 1185s, 1093m, 1044s, 960w, 823w, 800m, 795m 155.5, 149.7, 130.9, 127.6, 78.0, 76.9, 72.1, 70.7, 70.5, 52.1, 47.8, 47.3, 35.6, 24.3, 15.8, 14.8, 11.8 -[[(22bα,22cα,24bα,24cα,26bα, 26cα,28bα,28cα)-6, 14,21,22b,22c,24b,24c,26b,26c,28b,28c,29-dodecahydro-22b,22c,28b,28c-tetramethyl-7,9,11,13,22,24,26,28-octaoxo-7H,8H,9H,10H,11H,12H,13H,22H,23H,24H,25H,26H,27H, 28H-6a,7a,8a,9a,10a,11a,12a,13a,21a,22a,23a,24a,25a,26a,27a, 28a-hexadecaazacycloocta[1,2,3:3″,4″;5,6,7 5, 155,7, 149.7, 132.0, 131.6, 127.8, 126.7, 78.3, 77.2, 71.7, 71.2, 71.0, 52.7, 48.4, 47.6, 41.6, 35.6, 24.7, 22.9, 21.0, 15.5, 14.8 Sodium 3,3′-((2,3-dimethyl-1,4-phenylene)bis(oxy))bis(propane-1-sulfonate) (3d). A solution of 4 (18 g, 0.15 mol) in 1,4-dioxane (130 mL) was added into a solution of 2,3-dimethylhydroquinone (8.0 g, 58 mmol) in aqueous NaOH solution (1.0 M, 0.10 L). The mixture was stirred at rt for 12 h and then filtered to collect the crude solid. The solid was stirred with acetone (0.20 L) and then dried under high vacuum to yield 3d as a pale red solid (18 g, 73%). Mp >280°C. IR (ATR, cm −1 ): 2938w, 2869w, 1625m, 1489m, 1472m, 1205s, 1157s, 1112s, 1059s, 801m, 624m, 551m. 1 H NMR (400 MHz, D 2 O): δ 6.88 (s, 2H), 4.10 (t, J = 5.6, 4H), 3.10 (t, J = 7.2, 4H), 2.15−2.05 (m, 8H), 1.71 (s, 6H). 13 C NMR (125 MHz, D 2 O, 1, 4-dioxane as internal reference): δ 150. 5, 127.6, 111.8, 68.2, 47.6, 24.1, 11 3′-((5,6,7,8-tetrahydronaphthalene-1,4-diyl) bis(oxy))-bis(propane-1-sulfonate) (3e). A solution of 4 (8.6 g, 70.0 mmol) in 1,4-dioxane (60 mL) was added to a solution of 7 (4.0 g, 28 mmol) in aqueous NaOH solution (1.0 M, 45 mL). The mixture was stirred at rt for 12 h and then filtered to collect the crude solid. The crude solid was stirred with acetone (0.10 L), filtered, and then dried under high vacuum to yield 3e as a white solid (7.6 g, 60%). Mp >280°C. IR (ATR, cm −1 ): 2946w, 2846w, 1652w, 1471w, 1256m, 1194s, 1094m, 1045s, 791w, 604w, 521w.
1 H NMR (400 MHz, D 2 O): δ 6.83 (s, 2H), 4.09 (t, J = 6.0, 4H), 3.08 (t, J = 6.2, 4H), 2.65−2.55 (m, 4H), 2.35− 2.15 (m, 4H), 1.75−1.60 (m, 4H). 5, 6, 7, . A solution of 6 (5.3 g, 33 mmol) in EtOH (0.16 L) was mixed with palladium on activated carbon (3.5 g, 10 wt %, 3.3 mmol). The mixture was stirred under H 2 gas (15 Psi) for 3 days at rt. The heterogeneous reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. After the residual solvent was removed under high vacuum, the product was obtained as a light purple solid (4. 57 g, 85%) . Characterization data matches the literature report. 
